Annual report pursuant to Section 13 and 15(d)

Long-Term Debt and Other Financings - Novartis Note (Details)

v3.20.4
Long-Term Debt and Other Financings - Novartis Note (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Oct. 21, 2020
May 31, 2005
Dec. 31, 2020
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2017
Dec. 31, 2015
Sep. 30, 2015
Long-term debt                
Debt amount     $ 20,852 $ 20,852        
Revenue from contracts with customers       $ 27,941 $ 17,276      
Novartis Note                
Long-term debt                
Research and development expenses funded through loan facility, maximum (as a percent)   75.00%            
Maximum borrowing capacity under loan agreement   $ 50,000            
Interest rate at period end (as a percent)     2.26% 2.26%        
Amount by which note will be reduced upon achievement of specified milestones               $ 7,300
Debt amount     $ 9,100 $ 9,100 15,900      
Reduction in debt obligation $ 7,300              
Novartis Note | Six-month LIBOR                
Long-term debt                
Basis spread on variable rate   2.00%            
Novartis International | License Agreement                
Long-term debt                
Revenue from contracts with customers $ 25,000   $ 25,000 $ 25,000 $ 0 $ 10,000 $ 37,000